Anal Canal Cloacogenic Carcinoma clinical trials at UC Cancer
1 research study open to eligible people
A Study of Experimental Nivolumab After Combined Modality Therapy For High Risk Stage II-IIIB Anal Cancer
open to eligible people ages 18 years and up
This randomized phase II clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
at UC Davis UCSF